Gilead Sciences (Australia)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (Australia), Australia, covering academic research published from 2002 to 2024. Read More.
Open Access Percentage
71%
Total
Publications
84
Total Open
Publications
60
Total
Citations
4K
Open Access
Percentage
71%
Total
Publications
84
Total Open
Publications
60
Total
Citations
4K
Breakdown
Publisher Open
31%
Both
25%
Other Platform Open
15%
Closed
29%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 40%
18
Hybrid 20%
9
No Guarantees 40%
18
Other Platform Open
Domain 79%
26
Institution 27%
9
Other Internet 15%
5
Preprint 0%
0
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 26 |
DOI | Other Internet | 5 |
University of New South Wales, Sydney, Australia - UNSWorks | Institution | 2 |
RISalud Institutional Health Repository of Andalucía | Institution | 2 |
UNSW Sydney - UNSWorks | Institution | 1 |
University of Zaragoza Repository - Zaguan | Institution | 1 |
University of Modena and Reggio Emilia - IRIS UNIMORE | Institution | 1 |
University of Melbourne - Minerva Access | Institution | 1 |
University of Bristol - Bristol Research | Institution | 1 |
Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona | Institution | 1 |